ADC Therapeutics
ADCT
37 hedge funds and large institutions have $156M invested in ADC Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 12 closing their positions.
196% more call options, than puts
Call options by funds: $902K | Put options by funds: $305K
176% more capital invested
Capital invested by funds: $56.4M → $156M (+$99.4M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3.89% more ownership
Funds ownership: 38.15% → 42.04% (+3.9%)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
3% less funds holding
Funds holding: 38 → 37 (-1)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.15M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.69M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.13M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.85M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.13M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.32M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$1.68M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.22M |
| 5 |
Jane Street
New York
|
-$274K |
ADCT Hedge Fund Activity: Q1 2024 in Review
37 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2024, worth a combined $156M — up 176% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ADCT and 11 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $7.15M. The largest seller was Millennium Management, cutting an estimated $6.13M.
- 37 institutional investors held ADC Therapeutics (ADCT) as of Q1 2024, down from 38 in Q4 2023.
- Funds reported $156M of ADC Therapeutics stock for Q1 2024, up 176% quarter-over-quarter.
- 11 funds opened new ADC Therapeutics positions in Q1 2024 and 12 closed out, a net change of -1 holder.
- The largest ADC Therapeutics buyer in Q1 2024 was Morgan Stanley, an estimated $7.15M added.
- The largest ADC Therapeutics seller in Q1 2024 was Millennium Management, an estimated $6.13M sold.
Based on aggregated 13F filings for Q1 2024.